This Viewpoint describes the high cost of new cancer therapies, making comparisons to the early years of the AIDS epidemic, when many patients in low-resource countries died because of the initial high cost of HIV medications.
This case-control study analyzed the entire coding region of the FANCM gene to find its association with breast and ovarian cancer risk.
This Special Communication examines the development of a standard set of value-based patient-centered outcomes for breast cancer.
This review discusses the advantages and disadvantages of molecular imaging for use in oncologic clinical trials as well as clinical practice settings.
This population-based study assesses the effect of the decline in prostate-specific antigen screening and incidence on prostate cancer presentation.
This Viewpoint argues that surgery is not necessary for all patients with rectal cancer who respond to chemoradiation.
This Viewpoint argues that that it is premature to practice selective withdrawal of surgery based on the curative contribution of surgery, the lack of reliable predictive biomarkers, and the scarcity of solid evidence in support of this practice.
This study examined whether African American women are more susceptable to triple-negative breast cancer.
This randomized clinical trial investigates whether common variants in vitamin D and calcium pathway genes modify the effects of vitamin D3 or calcium supplementation on colorectal adenoma recurrence.
This systematic review compares outcomes and toxic effects between thoracic radiation with either cisplatin-etoposide or carboplatin-paclitaxel for patients with stage III non–small-cell lung cancer.
This study compares reports from 2 next-generation sequencing tests to determine the level of concordance between platforms.
This study describes cancer in a 255-million-year-old mammalian forebear and comments on the implications for establishing the phylogenetic and physiologic conditions under which such pathologic conditions first arose.
This study attempts to determine whether there are intrinsic subtype differences between primary breast cancer tumors and matched brain metastases (BrM) and to uncover BrM-acquired alterations that are clinically actionable.
This Viewpoint discusses quality measures for colorectal, breast, prostate, and lung cancer.
This randomized clinical trial assesses whether the addition of onartuzumab, a MET antibody, to first-line fluorouracil, leucovorin, and oxaliplatin therapy improves efficacy outcomes in HER2-negative, MET-positive gastroesophageal adenocarcinoma.